- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Releases Advisory Committee Report on Amgen's PCSK9 Inhibitor
A preliminary review of Amgen's evolocumab antibody (Repatha) by the Endocrinologic and Metabolic Drugs Advisory Committee, raises a few safety concerns and a call for ongoing monitoring, especially in patients with a high-risk of cardiovascular disease.
While the high price of cholesterol-lowering PCSK9 inhibitors, being developed by Amgen and Regeneron/Sanofi, has been in the news for some time now, FDA made progress in decisions on the clinical front. Yesterday, FDA released a report of its Endocrinologic and Metabolic Drugs Advisory Committee on Amgen's PCSK9 inhibitor evolocumab (Repatha).
Some of the topics of discussion by the committee included:
1. Overall drug safety based on the clinical development program.
2. Optimal and safe dose for using the antibody as a cholesterol-lowering agent and to treat homozygous familial hypercholesterolemia.
3. Whether the drugs cholesterol-lowering effect is sufficient to reduce a person's cardiovascular risk.
The committee raised safety issues, specifically asking for long-term studies and the need to assess risk in patients with a high cardiovascular disease burden who are on the highest dose of statins. Additionally, if approved, the committee called for addressing some observed safety concerns like pancreatitis and renal disorders with appropriate labeling.
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
